Hepion Pharmaceuticals Successfully Completes Application to the OTCQB
Hepion Pharmaceuticals (OTCQB:HEPA), a clinical stage biopharmaceutical company, has announced its successful transition to the OTCQB Venture Market. The company's common stock commenced trading on the OTCQB on June 25, 2025, under the symbol HEPA.
Hepion focuses on developing and commercializing diagnostic tests for multiple conditions including celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori, and hepatocellular carcinoma (HCC).
Hepion Pharmaceuticals (OTCQB:HEPA), un'azienda biofarmaceutica in fase clinica, ha annunciato il suo passaggio con successo al mercato OTCQB Venture. Le azioni ordinarie della società hanno iniziato a essere negoziate sull'OTCQB il 25 giugno 2025, con il simbolo HEPA.
Hepion si concentra sullo sviluppo e la commercializzazione di test diagnostici per diverse patologie, tra cui la celiachia, il multiplex respiratorio (Covid/Influenza A/B e RSV), l'Helicobacter pylori e il carcinoma epatocellulare (HCC).
Hepion Pharmaceuticals (OTCQB:HEPA), una empresa biofarmacéutica en etapa clínica, ha anunciado su exitosa transición al mercado OTCQB Venture. Las acciones comunes de la compañía comenzaron a cotizar en OTCQB el 25 de junio de 2025, bajo el símbolo HEPA.
Hepion se enfoca en desarrollar y comercializar pruebas diagnósticas para múltiples condiciones, incluyendo la enfermedad celíaca, multiplex respiratorio (Covid/Influenza A/B y RSV), helicobacter pylori y carcinoma hepatocelular (HCC).
Hepion Pharmaceuticals (OTCQB:HEPA)는 임상 단계의 생명공학 제약 회사로, OTCQB 벤처 마켓으로의 성공적인 이전을 발표했습니다. 회사의 보통주는 2025년 6월 25일부터 OTCQB에서 HEPA라는 심볼로 거래를 시작했습니다.
Hepion은 셀리악병, 호흡기 다중진단(Covid/인플루엔자 A/B 및 RSV), 헬리코박터 파일로리, 간세포암(HCC) 등 여러 질환에 대한 진단 테스트 개발 및 상용화에 집중하고 있습니다.
Hepion Pharmaceuticals (OTCQB:HEPA), une société biopharmaceutique en phase clinique, a annoncé sa transition réussie vers le marché OTCQB Venture. Les actions ordinaires de la société ont commencé à être négociées sur l'OTCQB le 25 juin 2025, sous le symbole HEPA.
Hepion se concentre sur le développement et la commercialisation de tests diagnostiques pour plusieurs affections, notamment la maladie cœliaque, le multiplex respiratoire (Covid/Grippe A/B et RSV), Helicobacter pylori et le carcinome hépatocellulaire (CHC).
Hepion Pharmaceuticals (OTCQB:HEPA), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, hat seinen erfolgreichen Übergang zum OTCQB Venture Market bekannt gegeben. Die Stammaktien des Unternehmens wurden am 25. Juni 2025 unter dem Symbol HEPA an der OTCQB gehandelt.
Hepion konzentriert sich auf die Entwicklung und Vermarktung von diagnostischen Tests für verschiedene Erkrankungen, darunter Zöliakie, respiratorisches Multiplex (Covid/Influenza A/B und RSV), Helicobacter pylori und hepatozelluläres Karzinom (HCC).
- None.
- Downgrade from previous listing to OTCQB market indicates potential delisting concerns
- Trading on OTCQB typically means reduced liquidity and institutional investor access compared to major exchanges
MORRISTOWN, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTCQB:HEPA), a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori) and hepatocellular carcinoma (HCC), today announced that it has successfully completed the process of transitioning to the OTCQB Venture Market. The Company’s common stock begins trading on the OTCQB Venture Market today, June 25, 2025 with the trading symbol, HEPA.
About Hepion Pharmaceuticals
Hepion is a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori) and hepatocellular carcinoma.
For further information, please contact:
Hepion Pharmaceuticals
info@hepionpharma.com
FAQ
What does Hepion Pharmaceuticals' (HEPA) move to OTCQB mean for investors?
What diagnostic tests is Hepion Pharmaceuticals (HEPA) developing?
When did Hepion Pharmaceuticals (HEPA) begin trading on the OTCQB?
What is Hepion Pharmaceuticals' new trading symbol on the OTCQB?
